ATTD: Advanced Technologies and Treatments for Diabetes

Welcome back to ATTD Diabetes Talks! In Episode 5 of our series, The Power of Weekly Insulin, host Diana Isaacs is joined by Marissa Bowdler, PharmD, BCACP, TTS (Ambulatory Care Clinical Specialist in Endocrinology at Indiana University Health), to discuss critical strategies for managing and preventing hypoglycemia with weekly insulin therapy.

In this episode, we cover:

•

How hypoglycemia risk with weekly insulin compares to daily basal insulin

•

Key patient and treatment risk factors for hypoglycemia

•

Essential preventative strategies when initiating weekly insulin therapy

•

Patient education techniques for recognizing and managing hypoglycemia

•

Recommended clinical approaches for treatment

•

The role of Continuous Glucose Monitoring (CGM) and digital tech in hypoglycemia prevention

📌 Visit the ATTD Education Portal for exclusive content and resources: [ATTD Education Portal]

🔔 Subscribe to the channel and share this episode with colleagues advancing diabetes care!

This series is produced by Cue and supported by Eli Lilly & Company.

#Diabetes #Endocrinology #Hypoglycemia #WeeklyInsulin #ATTD #DiabetesCare #Pharmacy #CGM #HealthcareProfessionals

In this episode of ATTD Diabetes Talks: The Power of Weekly Insulin, host Diana Isaacs joins Dr. Alice Cheng to discuss practical strategies for starting and titrating weekly insulin in routine clinical practice.

Key Discussion Points:

•

Initiating weekly insulin therapy in routine clinical practice

•

Key considerations when determining the starting dose

•

How titration differs from daily basal insulin regimens

•

Recommended monitoring approaches during the initiation phase

•

Common challenges in early treatment and real-world strategies to overcome them

Guest: Dr. Alice Cheng (Professor at the University of Toronto; Endocrinologist at Trillium Health Partners and St. Michael’s Hospital)

You can find more resources on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field.

This series is supported by Eli Lilly & Company.

In this episode of ATTD Diabetes Talks, host Diana Isaacs is joined by Dr. Medha Munshi, Director of the Joslin Geriatric Diabetes Program and Professor of Medicine at Harvard Medical School. Together, they discuss the science behind weekly insulin, patient selection criteria, tailoring therapy to individual needs, and specific considerations for older or medically complex adults.

Key Takeaways:

•

Criteria & Patient Characteristics for Weekly Insulin

•

Managing Resistance, Comorbidities & Lifestyle

•

Benefits for Older Adults & Complex Patients

•

Individualizing Treatment & Best Practices

You can find more resources on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field.

This series is supported by Eli Lilly & Company.

In this episode, we explore the science behind weekly insulin, including the pharmacology of weekly insulin, its mechanism of action, how it differs from daily insulin formulations, and why it provides consistent control over a longer period.

Guest: Dr. Manasi Shah, Assistant Professor of Medicine at Eastern Virginia Medical School and Director of the Inpatient Diabetes Program at Sentara Norfolk General Hospital

Key discussion points:

•

What are the key pharmacokinetic properties that enable once-weekly insulin administration?

•

How does the pharmacodynamic profile differ from that of daily basal insulin formulations?

•

What mechanisms allow weekly insulin to provide sustained glucose control over several days?

•

How does this prolonged action translate into clinical glycemic stability?

•

What are the key pharmacological considerations clinicians should be aware of when interpreting data on weekly insulin?

•

What remaining scientific questions need to be addressed before broader clinical adoption?

You can find more resources on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field.

This series is supported by Eli Lilly & Company

In this inaugural episode of ATTD Diabetes Talks: The Power of Weekly Insulin, we delve into the evolution and future of basal insulin therapy. Host Diana Isaacs sits down with Dr. Rodolfo Galindo to explore the pharmacological innovations behind weekly insulin formulations and discuss how this breakthrough is reshaping modern diabetes management.

Guest: Dr. Rodolfo Galindo (Associate Professor of Medicine and Director of the Comprehensive Diabetes Center at the University of Miami Health System)

Key Topics Covered:

•

The Evolution of Basal Insulin: A look back at the progression from early long-acting formulations to current weekly treatment options.

•

Pharmacological Innovation: Understanding the science that makes weekly insulin formulations possible.

•

Clinical Advantages: Exploring the theoretical benefits of weekly versus daily basal insulin.

•

Patient Impact: Examining how shifting to a weekly regimen affects treatment burden and overall patient experience.

•

Future Outlook: How weekly insulin is poised to fit into the broader landscape of diabetes care.

Resources:

•

For more in-depth knowledge and exclusive content, visit the ATTD Education Portal.

Subscribe to the podcast to stay updated on the latest in diabetes management.

Join host Dr. David Ahn and guest Dr. Michael Haller (Professor and Chief of Pediatric Endocrinology at the University of Florida and Chair of TrialNet) as they take a comprehensive review of the evidence base and remaining gaps for inhaled insulin use in pediatric and adolescent populations

In this final episode, we dive into:

•

Key Challenges in Pediatrics: Unmet needs in pediatric insulin therapy, including injection fatigue and tech-retention issues for active youth.

•

The INHALE-1 Study: A deep dive into the randomized controlled trial data of 230 youth, highlighting efficacy, per-protocol non-inferiority, less weight gain, and superior treatment satisfaction among kids and parents.

•

Safety Profile: Analyzing forced expiratory volume (FEV1) data showing an excellent safety signal with no differences in pulmonary function or severe hypoglycemic events.

•

Practical Toolkit Use Cases: How the unique pharmacokinetic profile of inhaled insulin provides unmatched benefits for covering adrenaline-rush highs and avoiding hypoglycemia tail effects during sports and exercise.

•

Dosing Guidelines: Overcoming the practical "paradigm shift" of converting injected units to inhaled units and managing dosing effectively.

•

Future Horizons: Anticipating the "INHALE FIRST" study investigating early onboarding for newly diagnosed patients and introducing a new two-unit inhaled insulin cartridge.

About ATTD Diabetes Talks:

A podcast series dedicated to providing healthcare professionals with the latest knowledge and best practices in diabetes management, supported by MannKind Corporation.

Find more resources on the ATTD Education Portal:https://unlok-education.com/attd/

Subscribe to the podcast for more updates on advancing diabetes care.

#DiabetesManagement #PediatricEndocrinology #InhaledInsulin #ATTD #DiabetesCare #MedicalPodcast #Type1Diabetes

Chapters:

00:00 Intro and Unique Challenges in Pediatric Diabetes Management

02:38 The INHALE-1 Study: Efficacy, Satisfaction, and Weight Findings

06:27 Safety Signals, Pulmonary Function, and Adherence Challenges

10:18 Practical Toolkit Use Cases: Managing Sports and Exercise

12:48 Dosing Conversions and Practical Patient Selection Guidelines

15:02 Off-Label Integration with Automated Insulin Delivery (AID) Systems

20:14 Caregiver & School Nurse Roles and Managing Safety Concerns

22:00 Research Gaps, The INHALE FIRST Trial, and Wrap Up

Join host Dr. David Ahn and guest Dr. Roy Beck (Founder and Medical Director of the Jaeb Center for Health Research) as they explore the integration of inhaled insulin with automated insulin delivery (AID) systems.

In this episode, we dive into:

•

The potential of combining inhaled insulin with current AID technologies.

•

Theoretical advantages, including postprandial management.

•

Current evidence, clinical considerations, and existing evidence gaps.

•

Practical insights for clinicians on patient education and system integration.

About ATTD Diabetes Talks:

A podcast series dedicated to providing healthcare professionals with the latest knowledge and best practices in diabetes management, supported by MannKind Corporation.

Find more resources on the ATTD Education Portal: https://unlok-education.com/attd/

Subscribe to the podcast for more updates on advancing diabetes care.

#DiabetesManagement #AIDSystems #InhaledInsulin #ATTD #DiabetesCare #MedicalPodcast #Endocrinology

Chapters:

00:00 Intro

03:03 How Inhaled Insulin Works

07:30 Real World Dosing Workflow

10:24 Exercise and Safety Upside

15:45 Clinician Education Tips

17:38 Research Gaps and Trials Needed

19:32 Future Potential and Wrap Up

In this episode, we examine the concept of "therapeutic inertia" in diabetes care. Dr. David Ahn is joined by Dr. Grazia Aleppo, Professor of Medicine at the Feinberg School of Medicine, Northwestern University, to explore how inhaled insulin can help address the clinical and behavioral barriers often associated with insulin initiation.

Key discussion points:

•

Defining therapeutic inertia in the context of insulin initiation.

•

Common clinician and patient-related barriers that contribute to treatment delays.

•

Practical strategies for introducing inhaled insulin to hesitant patients.

•

System-level considerations, including workflow and reimbursement challenges.

Find more resources and exclusive content on the ATTD Education Portal: https://unlok-education.com/attd/

Make sure to subscribe to the ATTD Diabetes Talks podcast for more insights and updates. Let’s advance diabetes care together.

#DiabetesCare #Endocrinology #InhaledInsulin #ATTD #MedicalPodcast

Chapters:

00:00 Why Inhaled Insulin Matters

00:34 Show Intro and Guest

01:22 Defining Therapeutic Inertia

02:19 Clinician Barriers to Insulin

03:49 Patient Fears and Hesitation

05:28 How Inhaled Insulin Helps

07:00 Best Fit Patient Scenarios

08:22 Talking to Hesitant Patients

10:39 Workflow and Coverage Hurdles

13:35 PFT Testing and Side Effects

14:47 Future Role and Wrap Up

In our new series, The Role of Inhaled Insulin, host Dr David Ahn looks at the practical implementation of inhaled insulin in clinical practice. He is joined by Dr Irl Hirsch.

They discuss:

•

Where inhaled insulin fits today within the overall insulin therapy landscape

•

The best candidates for inhaled insulin in routine clinical practice

•

Key clinical factors to guide decision-making

•

Practical first steps to initiating inhaled insulin

•

Approaches to titration

•

Monitoring strategies, particularly regarding pulmonary safety and glycemic outcomes

•

Shared decision-making and engaging patients

Dr Irl Hirsch is Professor of Medicine, in the Division of Metabolism, Endocrinology and Nutrition at the University of Washington School of Medicine.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In today’s episode, Dr Bob Gabbay is joined by Dr Elena Toschi to address the most common questions clinicians have when it comes to insulin therapy.

They discuss:

•

The most common mistakes or misconceptions in basal insulin initiation and management

•

Intensification strategies such as titration, adding prandial insulin, or using fixed-ratio combinations

•

Leveraging technologies to improve insulin adherence and outcomes

•

Managing hypoglycemia concerns and achieving glycemic targets

•

Addressing psychological and behavioral barriers to insulin use in everyday clinical practice

Dr Elena Toschi is Assistant Professor of Medicine at Harvard Medical School. She’s also Director of the Young Adult Program and a member of the Diabetes Technology Program at the Joslin Diabetes Center.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In today’s episode, Dr Bob Gabbay is joined by Dr Anne Peters to discuss personalized insulin approaches for complex populations.

They discuss:

•

Why personalization is particularly important in insulin therapy

•

The patient groups most in need of a tailored approach

•

How comorbidities or frailty influence insulin decision-making

•

Guidelines, flexibility, and local solutions

Dr Peters is a Professor of Medicine at the Keck School of Medicine of USC, and Director of the USC Clinical Diabetes Programs.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode, host Bob Gabbay and his guest, Diana Isaacs PharmD, break down common barriers to insulin adherence; from the common reasons people may struggle with insulin, to behaviour change approaches that can help clinicians support their patients.

They discuss:

•

The barriers most misunderstood by clinicians

•

Communication and motivational interviewing with patients

•

Emotional burden and fear of hypoglycemia

•

Practical strategies clinicians can use to support patients more effectively

•

The role of the wider diabetes healthcare team

Diana Isaacs is an Endocrine Clinical Pharmacist and Director of Education and Training in Diabetes Technology at the Cleveland Clinic.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode, host Bob Gabbay and his guest, Professor Simon Heller, discuss preventing and managing hypoglycemia, with a focus on the risks, recognition, and safety education.

They discuss:

•

Why hypoglycemia remains a major concern in insulin therapy

•

Key risk factors to keep in mind

•

Clinical signs or patient-reported symptoms

•

Prevention strategies

•

Importance of patient education

•

Balancing glycemic targets with hypoglycemia risk

Prof. Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, and Director of Research & Development at Sheffield Teaching Hospitals, NHS Foundation Trust.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode, host Bob Gabbay and his guest, Professor Tadej Battelino, Co-Chair of ATTD, discuss the latest technological innovations in diabetes, including delivery innovations, connected devices, titration support.

They discuss:

•

The new technologies making the biggest difference in insulin therapy today

•

The role of smart pens, connected devices, and apps

•

Biggest clinical impact - including adherence, titration and outcomes

•

Accessibility of these tools in real-world practice

•

Advisor role of AI

•

The promising future of technology in insulin therapy and a functional cure

Professor Tadej Battelino is Co-Chair of ATTD and Chair of International Diabetes Federation Europe.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode, host Bob Gabbay and his guest, Dr George Grunberger, Chairman of the Grunberger Diabetes Institute, discuss best practice and guidance around basal insulin and GLP-1 combinations.

They discuss:

•

What exactly fixed-ratio combinations are and the problems they tackle

•

Identifying patient candidates and timelines for starting FRCs

•

Meaningful benefits of FRCs compared with basal insulin alone

•

Concerns and limitations of FRCs

•

How guideline recommendations currently position FRCs in diabetes management

Dr George Grunberger, Chairman of the Grunberger Diabetes Institute in Michigan. George is also Clinical Professor of Internal Medicine at Wayne State University School of Medicine, and Professor of Internal Medicine at Oakland University William Beaumont School of Medicine.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode, host Bob Gabbay and his guest, Dr William Polonsky discuss safe and effective titration strategies, and the importance of collaborating with your patient.

They discuss:

•

The importance of titration in successful insulin therapy

•

Barriers to titration, including patient self-management

•

How clinicians can collaborate with patients in their titration journey

•

The importance of language used by clinicians

•

Practical tips for simplifying titration in busy clinical settings

Dr. Polonsky is President and Founder of the Behavioral Diabetes Institute, and Associate Clinical Professor in Psychiatry at the University of California.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode, host Bob Gabbay and his guest, Dr Osama Hamdy, discuss how clinicians can identify patients for insulin initiation in Type 2 diabetes.

They discuss:

•

When clinicians should consider insulin for patients with T2D

•

Addressing concerns of weight gain with insulin

•

ADA/EASD recommendations

•

Barriers to insulin therapy and Type 2 diabetes

•

Advice on communication with patients

Dr Osama Hamdy is Associate Professor of Medicine at Harvard Medical School, and Director of the Obesity Clinical Program at the Joslin Diabetes Center.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In our new series, Insulin in Practice, host Dr Bob Gabbay looks at the principles of Basal Insulin Therapy in Type 2 Diabetes; its physiological role, pharmacodynamics, and current guideline-based use.

He is joined by Dr Giulio Romeo.

They discuss:

•

The role of basal insulin in normal physiology and why it matters in Type 2 diabetes

•

Goals of basal insulin therapy

•

What makes new basal insulins different

•

Current guidelines and recommendations for basal insulin therapy

•

Alternatives to basal insulin therapy

•

Tips for safe and effective initiation and titration

Dr Giulio Romeo is Associate Medical Director of the Adult Diabetes Section at Joslin Diabetes Center, and Assistant Professor of Medicine, Harvard Medical School.

Explore more on the ATTD Education Portal. Register now to access exclusive content and stay ahead in the field!

Make sure you’re subscribed to the ATTD Podcast feed today. Leave us a review and share with a colleague.

In this episode of ATTD 2026 Conference Catch-Up, we dive into Advancements in Type 1 Diabetes: From Pathogenesis to Therapy, featuring the latest breakthroughs in understanding and treating Type 1 diabetes, from viral triggers to novel treatment strategies.

Join us as we summarize key takeaways from these thought-provoking presentations:

•

Role of Viruses in Pathogenesis of Type 1 Diabetes – Dr. Teresa Rodriguez-Calvo

•

Dendritic Cells for Treatment of Type 1 Diabetes – Dr. Jason Gaglia

•

C-Peptide: A Marker for Functional Beta Cell Mass? – Prof. Chantal Mathieu

This episode is an essential listen for endocrinologists, researchers, and healthcare professionals specializing in diabetes care, providing insights into the evolving landscape of Type 1 diabetes pathogenesis and the potential of dendritic cell therapies.

Enjoy the listen!

This podcast was created using AI to provide a quick and insightful summary of an ATTD 2026 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.

ATTD 2026, the 19th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on 11-14 March, 2026, in Barcelona. https://attd.kenes.com/

In this episode of ATTD 2026 Conference Catch-Up, we dive into ATTD AI School for Clinicians: From GenAI Foundations to Agentic CDSS Workflows - Safe, Practical Use in Diabetes Care, where we explore the application of AI technologies in diabetes care, focusing on safety, ethics, and practical use.

Join us as we summarize key takeaways from these thought-provoking presentations:

•

Welcome & Framing – Dr. Amit Dey & Prof. Peter Schwarz

•

Foundations of AI & Gen-AI for Clinicians – Dr. Amit Dey

•

Agentic AI & CDSS Workflows in Diabetes Care – Dr. Revital Nimri

•

Ethics, EU AI Act & GDPR Essentials for Clinicians – Lucía Feito Allonca

This episode is an essential listen for clinicians, diabetes specialists, and healthcare professionals seeking to understand the practical, safe, and ethical integration of GenAI and AI-driven clinical decision support systems (CDSS) in diabetes care.

Enjoy the listen!

This podcast was created using AI to provide a quick and insightful summary of an ATTD 2026 session. While every effort has been made to ensure accuracy, listeners are encouraged to refer to original conference materials and recordings for detailed information.

ATTD 2026, the 19th International Conference on Advanced Technologies & Treatments for Diabetes, is taking place on 11-14 March, 2026, in Barcelona. https://attd.kenes.com/